EMERGENT BIOSOLUTIONS INC. Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent
EMERGENT BIOSOLUTIONS INC. (EBS) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent of -$7.50 million for the 12-month period ending 2022-12-31, per its 10-K/A filed 2023-12-11.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent · last filed 2023-12-11
- EMERGENT BIOSOLUTIONS INC. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2019-03-31 was $200.00K.
- EMERGENT BIOSOLUTIONS INC. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2022 was -$7.50M.
- EMERGENT BIOSOLUTIONS INC. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2021 was -$3.70M, a 186.05% decline from fiscal 2020.
- EMERGENT BIOSOLUTIONS INC. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2020 was $4.30M, a 34.38% increase from fiscal 2019.
- EMERGENT BIOSOLUTIONS INC. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2019 was $3.20M, a 1500.00% increase from fiscal 2018.
| Period end | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 3 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 12 month |
|---|---|---|
| 2022-12-31 | -$7.50M 10-K/A · filed 2023-12-11 | |
| 2021-12-31 | -$3.70M 10-K/A · filed 2023-12-11 | |
| 2020-12-31 | $4.30M 10-K/A · filed 2023-12-11 | |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $3.20M 10-K · filed 2022-02-25 | |
| 2019-03-31 | $200.00K 10-Q · filed 2020-05-01 | |
| 2018-12-31 | $200.00K 10-K · filed 2021-02-19 | |
| 2017-12-31 | $0.00 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |